statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Head of Institutional Equities at HDFC Securities expects consumption demand to witness a slight pickup in FY25 and suggests adding exposure to the FMCG sector on a selective basis.

Daily Voice | These 4 pharma stocks to benefit from change in 2 trends: HDFC Securities' Unmesh Sharma

Dadra's specialization lies in the production of oral solid dosage forms and the manufacture of the blockbuster drug Revlimid, a vital revenue driver for Sun Pharma's generics segment.

US FDA releases details of OAI observations at Sun Pharma’s Dadra plant

The official action indicated classification for the Dadra unit by FDA follows similar trouble at Sun Pharma's Halol and Mohali facilities recently, which hit generic sales

Another regulatory blow for Sun Pharma after Dadra unit tagged 'OAI' by US FDA, stock down

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Steady US sales to bring a healthy quarter for pharma sector

KR Choksey is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1827 in its research report dated March 19, 2024.

Buy Sun Pharmaceuticals; target of Rs 1827: KR Choksey

The approval is for Winlevi (clascoterone cream 1 per cent), which is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older, the company said in a statement.

Sun Pharma gets regulatory nod in Australia for acne treatment cream

Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1727 in its research report dated March 11, 2024.

Buy Sun Pharmaceutical Industries; target of Rs 1727: Sharekhan

As per the USFDA, the company has initiated the Class II nationwide (US) recall on March 4 this year.

Sun Pharma recalls 55,000 bottles of generic drug from US market due to manufacturing norms violation

The USFDA classified the unit as No Action Indicated, paving the way for manufacturing and export from the plant, a CNBC Awaaz report said

Sun Pharma hits 52- week high on USFDA all-clear to Ankleshwar unit

Indian generic companies have benefited from the continuing shortages and approval slowdown in the US.

Strong India growth, benign price erosion in the US drive Q3 earnings for Indian pharma

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Watchers	4,878
52-Wk Low	922.45
52-Wk High	1,638.85

Volume	1.03M
52-Wk High	1,638.85
52-Wk Low	922.45

SUNPHARMA.NSE Sun Pharmaceutical Industries Ltd.

About

Feed

News

Sentiment

Fundamentals